EGFR AUTOCRINE ACTIVATION

CI-VAR-00000178Explore in graph →CIViC 309

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
EGFR AUTOCRINE ACTIVATION	Crizotinib	Predictive	B	Supports Resistance	2	rejected	EID769 Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions. PMID 23344087 · Kim et al., 2013 · Open in CIViC	civic
EGFR AUTOCRINE ACTIVATION	Crizotinib	Predictive	D	Supports Resistance	3	rejected	EID768 A cell line (DFCI076 ) with EML1-ALK fusion and resistance mutation L1152R showed no response to ALK inhibition with crizotinib or TAE684. There was co-dependancy on AKT and EGFR-signaling and inhibit… (full text at CIViC) PMID 21791641 · Sasaki et al., 2011 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.